載入...
Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study
BACKGROUND: Bisphosphonates are recommended for use as first-line therapy for the prevention and treatment of glucocorticoid-induced osteoporosis in adults. However, the appropriate usage of bisphosphonates for the prevention or treatment of glucocorticoid-induced osteoporosis in children remains un...
Na minha lista:
| 發表在: | Pediatr Rheumatol Online J |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6006935/ https://ncbi.nlm.nih.gov/pubmed/29914510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12969-018-0258-5 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|